Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
CRISPR Therapeutics AG | Chief Financial Officer | Common Shares | 5.07K | $317K | $62.50 | Feb 21, 2023 | Direct |
CRISPR Therapeutics AG | Chief Financial Officer | Restricted Stock Units | 11.5K | Feb 18, 2023 | Direct | ||
Translate Bio, Inc. | Chief Financial Officer | Stcok Option (right to buy) | 0 | Sep 14, 2021 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
CRSP | CRISPR Therapeutics AG | Feb 18, 2023 | 3 | -$67.2K | 4 | Feb 22, 2023 | Chief Financial Officer |
CRSP | CRISPR Therapeutics AG | Oct 14, 2022 | 3 | -$61.9K | 4 | Oct 18, 2022 | Chief Financial Officer |
CRSP | CRISPR Therapeutics AG | Oct 7, 2022 | 1 | $0 | 4 | Oct 12, 2022 | Chief Financial Officer |
CRSP | CRISPR Therapeutics AG | Aug 16, 2022 | 1 | $0 | 4 | Aug 18, 2022 | Chief Financial Officer |
CRSP | CRISPR Therapeutics AG | Feb 18, 2022 | 2 | $0 | 4 | Feb 22, 2022 | Chief Financial Officer |
CRSP | CRISPR Therapeutics AG | Oct 14, 2021 | 2 | $0 | 4 | Oct 18, 2021 | Chief Financial Officer |
CRSP | CRISPR Therapeutics AG | Oct 14, 2021 | 0 | $0 | 3 | Oct 15, 2021 | Chief Financial Officer |
TBIO | Translate Bio, Inc. | Sep 14, 2021 | 1 | $0 | 4 | Sep 14, 2021 | Chief Financial Officer |